Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
OPERATING ACTIVITIES    
Net loss $ (324) $ (368)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Provision for doubtful accounts 114 47
Depreciation 2,955 2,706
Loss on disposal of and reserve adjustments for medical equipment 450 275
Gain on sale of medical equipment (883) (228)
Amortization of intangible assets 248 710
Amortization of deferred debt issuance costs 18 18
Stock-based compensation 720 1,047
Deferred income taxes (302) (462)
Changes in assets - (increase)/decrease:    
Accounts receivable (961) (1,278)
Inventories (823) 61
Other current assets (830) (50)
Other assets (846) (41)
Changes in liabilities - increase:    
Accounts payable and other liabilities 313 1,641
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES (151) 4,078
INVESTING ACTIVITIES    
Purchase of medical equipment (3,968) (2,931)
Purchase of property and equipment (317) (178)
Proceeds from sale of medical equipment, property and equipment 1,234 966
NET CASH USED IN INVESTING ACTIVITIES (3,051) (2,143)
FINANCING ACTIVITIES    
Principal payments on long-term debt (13,683) (10,696)
Cash proceeds from long-term debt 16,894 12,529
Common stock repurchased as part of share repurchase program (153) (4,006)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (324) (54)
Cash proceeds from stock plans 559 511
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 3,293 (1,716)
Net change in cash and cash equivalents 91 219
Cash and cash equivalents, beginning of period 165 186
Cash and cash equivalents, end of period $ 256 $ 405